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CObjectives: To compare in patients with inflammatory bowel dis-
ease the performance of a value set for the EQ-5D based on experi-
enced health states (EHSs) with value sets based on given health
states (GHSs). Methods: A value set based on EHSs and valuation by
he visual analogue scale (VAS) in the German general population
as compared with a German and a UK value set, both based on
HSs and time-trade off valuation. Accuracy in the prediction of
ctual VAS ratings by patients was assessed using correlation and
ean absolute error. Construct validity was tested by correlation
ith established disease activity indices and test-retest reliability by
ntraclass correlation between two measurements. Data originated
rom a survey of 270 patients with Crohn’s disease and 232 patients
ith ulcerative colitis. Results: EHS-VAS correlates best with actual
AS ratings for all patients but not for all subgroups. EHS-VAS has
he lowest mean absolute error for almost all analyzed groups ex- O
nom
al So
doi:10.1016/j.jval.2011.08.004ept for measured differences between two time points. Regarding
est-retest reliability in all patients, EHS-VAS correlations were clos-
st to those of actual VAS ratings. Conclusion: EHS-VAS renders ex-
erience-based valuations but not decision utilities. GHS-based ap-
roaches cover severe health states more extensively, but study
atients reported health states similar to those of a general popula-
ion. Compared to GHS time-trade off value sets, the EHS-VAS value
et predicted EQ-5D VAS valuations by patients with inflammatory
owel disease equally well and partly better. It performed partly
etter with respect to test-retest reliability and the same with re-
pect to construct validity.
eywords: Crohn’s disease, decision utility, EQ-5D index, experience-
ased valuation, ulcerative colitis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Preference-based valuations of health-related quality of life
have become a key endpoint in economic evaluation studies. If
such a valuation has not been elicited from patients or if the
valuations elicited do not fulfill the decision maker’s require-
ments, such as the use of certain valuation techniques or the
use of valuations that reflect the preferences of a specific pop-
ulation, then value sets may offer a useful alternative. Value
sets consist of estimates of the preference-based valuation for
all possible health states. Value sets have been developed for
various instruments measuring quality of life, for example,
for the EQ-5D, the Health Utility Index, and the SF-6D [1–3]. The
common standard is to estimate the value set from valuations
of given health states (GHSs) that are surveyed among a repre-
sentative sample of a national population. Valuations using the
time-trade off method (TTO) and the standard gamble are based
on weighted choices between a current health state and perfect
health; results are labeled decision utilities. Using the visual
analogue scale (VAS) only refers to one single health state and
renders just valuations. For the EQ-5D, empirical comparisons
have shown that such value sets may differ significantly by
valuation method and also between populations [4].
* Address correspondence to: Reiner Leidl, Institute for Health Eco
Postfach 1129, D-85758 Neuherberg, Germany.
E-mail: Leidl@helmholtz-muenchen.de.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.In assessing health outcomes, this article analyzes a perspec-
tive that attributes the top priority to patients’ experience of
health. The first choice is thus to have patients value their current
health state with a VAS. Using this method avoids that unexperi-
enced health states must be considered in the valuation. If value
sets are needed, they can be estimated from health states experi-
enced. Given a representative sampling for a population and ade-
quate estimation, such a value set reflects, for any specific health
state, the average valuation of its experience in that population.
For the EQ-5D, a value set based on experienced health states
(EHSs) and VAS valuation has been developed [5]. This method
may be of interest to decision makers who want to assess health
outcomes based on how health states are actually experienced by
their population. When tested in a population sample drawn a
year later, the values predicted by the EHS-based value set corre-
latedwell with patient-elicited VAS scores [5]. An extension of this
work, this study investigated the performance of the new ap-
proach in a clinical population.
Inflammatory bowel disease includes Crohn’s disease (CD) and
ulcerative colitis (UC). The prevalence of these diseases has been
increasing in most developed countries [6]. The diseases are
chronic, have an unpredictable course, and may be associated
with debilitating conditions and a reduction in quality of life [7].
ics and Health Care Management, Helmholtz Zentrum München,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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152 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 5 1 – 1 5 7The ability of a generic, preference-based instrument to measure
the impact on quality of life has been tested using the EQ-5D.
Studies found the EQ-5D to feature acceptable psychometric char-
acteristics, especially when compared to established disease-spe-
cific measures of quality of life [8,9].
The aim of this study was to test the performance of an EHS-
based value set in patients with inflammatory bowel disease. The
EQ-5D and the VAS are used as instruments to measure and value
health-related quality of life. The main criteria for performance
are accuracy in the prediction of health state valuations, validity
with respect to established measures of disease activity, and test-
retest reliability. To assess the EHS-based approach, its perfor-
mance is compared to that of existing value sets based on GHSs. In
this comparison, differences in the valuation methods on which
the value sets are based and the populations for which they are
estimated also have to be considered.
Methods and Data
Three value sets were analyzed in this study. For the EHS-based
value set, the 2006 estimate for Germany by Leidl and Reitmeir [5]
was used (EHS-VAS Germany). This value set reflects VAS valua-
tions of a representative sample (n 2032) of the German popula-
tion in 2006. To estimate the value set, a generalized linear model
had been used. Thismodelwas based on a binomial distribution of
the index estimated and included restrictions in the estimation of
parameters. This econometric specification ensured that esti-
mateswere limited to the range of 0 to 100 and that the rankings of
the valuations remained consistent. The Euro-Qol Group, which
developed the EQ-5D, recommends time-trade off valuation as the
preferred approach if decision utilities are to be derived by choice-
based elicitation techniques [1]. Typically, generalized least-square
regression is used to link the description of given health states and
time-trade off valuation. A value set based on thismethod is referred
to as GHS-TTO. The second value set investigated in this article fea-
tures the only study of this type for Germany. This study was con-
ducted by Greiner et al. [10] (GHS-TTOGermany) andwas based on a
sample size which was not very large (n  339). Thus, the study on
which it was methodologically based is also considered: the fre-
quently used value set by Dolan [11], whichwas derived from a large
survey (n2997) representative for thepopulationsof England, Scot-
land, andWales (GHS-TTO UK).
Patient sample
The data analyzed in this study consist of a sample of patients
with inflammatory bowel disease that was used for detailed test-
ing of the psychometric characteristics of the EQ-5D in measuring
health-related quality of life in this indication. Data were derived
from a cost and quality-of-life survey among patients registered
with the German patients’ association for inflammatory bowel
disease. The sample comprises 270 patients with CD and 232 pa-
tients with UC. Patients were asked to complete the EQ-5D and the
VAS at baseline (first measurement) and 4 weeks later (second
measurement). Themean age of respondentswas 42 years; almost
60% were female. The sample consists of a chronically ill popula-
tion: the average disease duration was 14 years; about 40% of pa-
tients reported active disease (as opposed to remission), and a
little more than 40% reported surgery for their disease. The mean
VAS was reported to be 75.0 by patients with CD and 79.6 by pa-
tients with UC. Further details regarding the survey, the sample,
descriptive results of the EQ-5D, and the psychometric character-
istics of the EQ VAS are reported elsewhere [9,12].
Performance measurement
Based on this patient survey, this study assessed the performance
of the three value sets. The actual VAS valuation of the patients isused as the gold standard; thus, GHSs are not incorporated in the
reference measure. It should be noted that the scales of the valu-
ation methods differ. For the VAS approaches, 100 represents the
best imaginable health state and 0 the worst imaginable health
state. For the TTO approach, 1 represents full health, which is
defined as a state with no problem in any of the five dimensions of
the EQ-5D, and 0 represents dead. Predictive performance is con-
sidered in terms of Pearson correlation between predicted and
actual valuation. Predictive accuracy is evaluated with mean ab-
solute error between predicted and actual valuation, using the
parametersmean, SD, andmedian. In a clinical context, value sets
should adequately reflect quality of life at different stages of the
disease. For three severity stages (inactive,mild,moderate/severe)
of CD patients and of UC patients, means and SDs of the estimates
are compared. To determine the disease activity of patients, the
answers of CD and UC patients to two questionnaires were used:
the Crohn’s Disease Activity Index [13] and the Clinical Activity
ndex [14], respectively. Because laboratory data were not avail-
ble, calculations were based on patient-reported data and evalu-
ted according to the methods reported by Janke et al. [15]. The
everity stages were defined as follows for both diseases: inactive,
to 3; slight, 4 to 7; moderate/severe, greater than 7. Furthermore,
orrelations and mean absolute errors are reported for CD and UC
atients as well as for all patients.
As a key aspect of the psychometric properties of EQ-5D
alue sets, the construct validity of the three value sets and that
f the actual VAS rating by patients were compared. The crite-
ion used was the Spearman rank correlation with established
isease activity indices, as described previously. The analysis of
est-retest reliability is restricted to those patients who re-
orted in the survey that their health state has been stable be-
ween the two measurements. Valuations, however, may differ
ue to changes in the descriptive part of the EQ-5D, and, in the
ase of patients’ valuation, due to a different VAS rating for the
ame health state. The test-retest reliability of valuations was
ested using the intraclass correlation coefficient between the
wo measurement points and compared between the valuation
pproaches.
Bootstrap methods were applied to estimate confidence in-
ervals for the correlation parameters, and bootstrap tests were
sed to test for differences between associated correlation co-
fficients. Differences between the value sets with respect to
he mean absolute error were tested by Wilcoxon signed rank
ests.
A final point is the coverage of health states by a value set. GHS
pproaches include several severe health states in their surveys
nd easily cover all 243 health states that the EQ-5D can assume.
n the study developing the EHS-based value set used, very severe
ealth states had not been reported [5]. For respective states, es-
imation has to be extrapolated. To analyze this issue, the distri-
utions of health states in the value sets and in the patient popu-
ation are compared by an overall problem score. For each of the
ve dimensions of the EQ-5D, a score of 1 is given for no problem,
for some problems, and 3 for severe problems. The overall prob-
em score is the sumof all 5 dimensions, ranging between 5 and 15.
his score summarizes the overall burden of problems reported,
hereas it does not differentiate between problems in different
imensions or various combinations of problems, which can re-
ult in the same overall score.
Results
Ninety-eight percent of the patients with inflammatory bowel dis-
ease completed the descriptive part of the EQ-5D and VAS at the
firstmeasurement; 87%did so at the secondmeasurement, and for
86% of patients, a difference could be calculated. The rate of
153V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 5 1 – 1 5 7complete responses is slightly higher for CD patients than for UC
patients.
Concerning all patients and both time points measured, the
standard approach, the GHS-TTO Germany, correlates about 0.66
with the VAS gold standard. The correlation of the differences in
measurements between the two time points is substantially lower
than the correlations of the originalmeasurements at the two time
points. Absolutely, the correlations of the GHS-TTO UK value set
with the actual VAS values of the patients are higher than those of
the GHS-TTO Germany value set. The value set of the EHS-VAS
Germany correlates significantly better with actual VAS valua-
tions than both GHS value sets for bothmeasurement time points.
This is also true for the correlations of the differences between
these time points. For CD patients, correlations of EHS-VAS Ger-
many with the gold standard are also significantly better than
those of the GHS value sets, except for the GHS-TTO UK value set
Table 1 – Pearson correlation  with 95% confidence interv
valuation by patient at two measurement points and the d
CD patients
n 
GHS-TTO UK
1st measurement 268 0.700 (0.617–0.772)
2nd measurement 234 0.728 * (0.650–0.790)
Difference 232 0.174 ** (0.034 to 0.359)
GHS-TTO Germany
1st measurement 268 0.653 ** (0.555–0.737)
2nd measurement 234 0.679 ** (0.584–0.749)
Difference 232 0.097 ** (0.123 to 0.305)
EHS-VAS Germany
1st measurement 268 0.734 (0.670–0.793)
2nd measurement 234 0.784 (0.722–0.832)
Difference 232 0.326 (0.150–0.482)
Note: n is the number of observations, 95% confidence interval in pa
CD, Crohn’s disease; EHS-VAS, experienced health states–visual ana
colitis; VAS, visual analogue scale.
* P 0.05, ** P 0.01, significance of bootstrap test for difference of co
states–visual analogue scale.
Table 2 – Mean absolute error of value predicted by value s
measurement points.
CD patients
n Mean SD Median n
GHS-TTO UK
1st measurement 268 12.0 ** 12.6 9.25 22
2nd measurement 234 11.7 ** 11.2 10.00 20
Difference 232 10.1 *** 14.8 5.00 19
GHS-TTO Germany
1st measurement 268 15.1 *** 12.0 11.89 22
2nd measurement 234 15.8 *** 12.8 12.18 20
Difference 232 8.9 13.7 5.00 19
EHS-VAS Germany
1st measurement 268 10.1 8.5 9.34 22
2nd measurement 234 9.7 7.4 9.34 20
Difference 232 7.9 9.2 5.00 19
Note: n is the number of observations; minimum mean absolute erro
CD, Crohn’s disease; EHS-VAS, experienced health states–visual ana
colitis; VAS, visual analogue scale.
*P  0.05, ** P  0.01, *** P  0.001 for the signed-rank test on the dianalogue scale.at the first measurement point. For UC patients, EHS-VAS Ger-
many correlates significantly better only for the second measure-
ment point (Table 1).
Details on the predictive accuracy are shown bymean absolute
errors, again for the two measurement time points and the differ-
ence between the two (Table 2). Considering the mean and SD of
mean absolute error, EHS-VAS Germany always had the lowest
values. The mean of this indicator of EHS-VAS Germany is signif-
icantly lower than that of the two GHS value sets except for GHS-
TTO UK at the first measurement point in UC patients and for the
differences measured by GHS-TTO Germany for all patients and
for the CD and UC patient subgroups. With respect to the median
of the absolute error, EHS-VAS Germany had the lowest value or a
median equal to the other value sets with two exceptions: the
median of the GHS-TTO UK value set was a 0.09 lower for CD
patients in the first measurement and themedian of the GHS-TTO
tween value predicted by value set and actual VAS
ence between the measurement points.
UC patients All patients
 n 
0.730 (0.660–0.796) 493 0.715 * (0.657–0.770)
0.658 ** (0.594–0.726) 435 0.712 ** (0.660–0.763)
0.331 (0.155–0.484) 429 0.225 ** (0.079–0.360)
0.683 (0.595–0.769) 493 0.665 ** (0.595–0.731)
0.587 ** (0.524–0.687) 435 0.657 ** (0.591–0.717)
0.299 (0.122–0.443) 429 0.160 * (0.004–0.321)
0.768 (0.705–0.822) 493 0.752 (0.709–0.795)
0.738 (0.667–0.803) 435 0.773 (0.729–0.815)
0.389 (0.206–0.540) 429 0.347 (0.217–0.455)
eses, maximum  of all three value sets in bold.
scale; GHS-TTO, given health states–time-trade off; UC, ulcerative
tion coefficient to the respective one achieved by experienced health
mpared with actual VAS valuation by patient: two
UC patients All patients
Mean SD Median n Mean SD Median
9.9 8.5 9.60 493 11.1 ** 11.0 9.60
10.9 ** 9.5 9.80 435 11.3 *** 10.4 10.00
7.5 ** 10.4 4.00 429 8.9 *** 13.0 5.00
12.8 *** 10.1 10.00 493 14.1 *** 11.2 10.00
14.5 *** 11.4 11.00 435 15.2 *** 12.2 11.59
6.3 8.5 3.40 429 7.7 11.7 5.00
8.5 6.9 6.66 493 9.4 7.9 8.59
8.8 6.9 8.59 435 9.3 7.2 8.69
6.0 7.4 4.00 429 7.0 8.5 5.00
ll three value sets in bold.
scale; GHS-TTO, given health states–time-trade off; UC, ulcerative
ce between the value set and the experienced health states–visualal be
iffer
n
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154 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 5 1 – 1 5 7Germany value set for the differences of UC patients was 0.6 lower
than that of the EHS-VAS.
The difference between the actual VAS rating by patients, i.e.,
the gold standard, and the three value sets is shown for three
stages of severity for CD and UC patients in Figure 1. For both
patient groups and all three value sets, every increase in severity
stage leads to a significantly smaller mean value (all P  0.01).
Overall, EHS-VAS Germany is closest to the gold standard in terms
of mean VAS valuation of health states. In none of the severity
stages does the difference in the gold standard exceed 10% of the
mean VAS. Greater differences exist between the gold standard
and the GHS-TTO value sets at one ormore stages for both CD and
UC patients.With respect to SD of VAS, EHS-VASGermany is again
closer to the gold standard except for GHS-Germany in the mean
severity stage of CD patients and the highest severity stage of UC
patients. In this highest severity stage of both CD and UC patients,
both GHS-TTO value sets overestimate the SD of VAS ratings,
whereas EHS-VAS Germany underestimates the dispersion of VAS
ratings.
Fig. 1 – Mean and SD of health state valuations using the EQ
patients with ulcerative colitis (UC) and Crohn’s disease (CD
128 except for VAS, n = 129; S2, n = 75 except for VAS, n = 7
for VAS, n = 137; S2, n = 57 except for VAS, n = 58; S3, n = 24
visual analogue scale; GHS-TTO, given health states–time-tr
Table 3 – Construct validity: Spearman rank correlation of
CD patients
VAS 0.688 (0.754 to 0.608)
GHS-TTO UK 0.746 (0.802 to 0.677)
GHS-TTO Germany 0.745 (0.803 to 0.676)
EHS-VAS Germany 0.747 (0.805 to 0.678)
Note: 95% confidence interval in brackets. Maximum Spearman rank
excluding the EHS-VAS Germany approach, see Stark et al. 2010 [9].
CD, Crohn’s disease; EHS-VAS, experienced health states–visual ana
colitis.For construct validity, the rank correlation of all value setswith
the respective disease activity index exceeds that of actual VAS
ratings for CD patients and for all patients, but not for UC patients.
Among the value sets, EHS-VAS Germany correlates best with the
disease activity indices for all patients and for both subgroups. The
value sets, however, are not significantly different in this respect
(Table 3).
Although both descriptive part and valuation can vary, test-
retest reliability is highest for actual VAS ratings by patients (Fig.
2). Among the value sets, EHS-VAS Germany had the highest in-
traclass correlations for all patient groups investigated. Referring
to actual VAS ratings, only the confidence intervals of the correla-
tion coefficients of the EHS-VAS Germany value set overlap with
this gold standard for all patients and for CD patients, whereas
none of the value sets achieve this for UC patients.
The coverage of health states in the study sample and in the
value sets is summarized in Figure 3. Study patients reported just
31 health states. The highest overall problem score was 12 com-
S and three value sets according to the severity stage of
te: CD patients by severity stages S1, S2, and S3. S1, n =
, n = 22. UC patients by severity stage: S1, n = 138 except
ept for VAS, n = 26. EHS-VAS, experienced health states–
off; VAS, visual analogue scale.
ctivity index with the value sets.
UC patients All patients
0.674 (0.738 to 0.593) –0.678 (0.724 to 0.616)
0.655 (0.725 to 0.572) 0.703 (0.751 to 0.646)
0.668 (0.737 to 0.586) 0.708 (0.755 to 0.654)
0.679 (0.748 to 0.604) 0.714 (0.760 to 0.661)
elation of all three value sets in bold. For correlations of subgroups
scale; GHS-TTO, given health states–time-trade off; UC, ulcerative-VA
). No
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155V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 5 1 – 1 5 7pared to 13 in the sample that the EHS-based value setwas derived
from.
Discussion
In the literature, health outcomes of a multinational trial on drug
treatment of UC patients have been expressed by the EQ-5D de-
scriptive part and then valuated by a GHS-TTO based value set
from the UK [16]. A decision maker who wanted to examine how
hese outcomes were experienced by patients and also to refer to
he German population could consider the following. In cases in
hich VAS valuations were available from the trial patients (as
ecommended by the EuroQol Group), these valuations would be
mportant, but coming from a multinational study, they would
eave open the question of differences in VAS valuation among
ountries. The EHS-based value set can be used as a transferability
ool to achieve comparable valuations according to the German
ontext. This even includes cases in which VAS valuations by pa-
ients were not available at all. Furthermore, a rough indication of
hether large differences exist in valuation between countries
ould be derived by comparing VAS valuations of patients and
aluations by the German EHS-based value set: For patients with
nflammatory bowel disease, findings of our study suggest that
esults from this value set would not be expected to differ bymore
han about 10 points from the VAS valuations of patients on aver-
ge, omitting any other influences on valuation (Table 2).
This is the first study to test such an EHS-VAS based value set in
a clinical population. By comparing the EHS-VAS values to the
actual VAS rating by a patient, the performance of the value set
could be analyzed in detail. It is important to understand that the
health outcomes measured by experience-based valuation are
theoretically different from decision utilities. EHS-based valua-
tions by patients do not reflect the preferences of the general pop-
ulation for health states before resource allocation, thus theoreti-
cal health states, but summarize the health state experienced
from the patient’s perspective. Decision makers and researchers
Fig. 2 – Test-retest reliability: intraclass-correlation
between measurements for patients who reported an
unchanged health state. Note: Thin lines indicate the 95%
confidence intervals. Patients with complete
measurements: CD patients, n = 194 except for VAS, n =
195; UC patients, n = 163 except for VAS, n=165; all
patients, n = 357 except for VAS, n = 360. For UC patients,
the lower bound of the confidence interval for VAS is 0.907,
whereas the upper bound for EHS-VAS Germany is 0.906.
EHS-VAS, experienced health states–visual analogue scale;
GHS-TTO, given health states–time-trade off; IBD,
inflammatory bowel disease.who require health outcomes to reflect choice-based decision util-ities may see this as a basic limitation. If the purpose, however, is
to measure the degree to which health outcomes are experienced
by patients rather than to integrate measures of how persons
choose among hypothetical health states, ratings based on actual
patients are the relevant comparators to choose. EHS-based ap-
proaches provide values that are averaged for a population and
reduce the variation of individualmeasurements.With EHS-based
approaches, preferences for health states of others would have to
be elicited in an extra step that derived the willingness to pay for
given health outcomes. GHS-based approaches integrate themea-
surement of health outcomes and preferences for health states of
others in one step.
A limitation of this study is that choosing the VAS as the gold
standard to judge the performance of the value sets provides some
advantage to the EHS-based concept as it also uses the VAS for
valuation and refers to the same scale. The extent to which the
valuation method used, TTO versus VAS, contributes to differ-
ences in performance has not been examined. There is an estima-
tion of a GHS-VAS based value set for the EQ-5D in Germany [17].
This value set, however, has been suspected to have framing ef-
fects of the survey design used [10] and was thus omitted in this
study. Despite these problems, a previous comparison of this GHS-
VAS approach with GHS-TTO and EHS-VAS in Germany suggested
that a major part of performance differences may be due to using
EHSs instead of GHSs rather than to the valuation method (see
Table V in ref. 5). Furthermore, the use of the VAS has been criti-
cally debated by the proponents of the decision utility approach,
e.g., because VAS is not a choice-based method and may have
spacing-out bias (for a brief summary, see Chapter 4.2 in ref. 1).
The literature, however, also provides theoretical support and
psychometrically favorable empirical evidence of the use of the
rating scale in health state valuation [5]. In this study, the perfor-
mance of GHSs from both Germany and the UK and EHS-based
approaches is also compared. However, among the GHS-based ap-
proaches, theUK value setmostly performed better than that from
Germany.
For patients with inflammatory bowel disease, this study
shows that the EHS-VAS based value set performed equally or
significantly better than the two GHS-based value sets in most of
the tests. This applies to correlation with the actual VAS rating as
well as predictive accuracy in terms of mean absolute error. Sta-
tistically significant advantages of the EHS-based approach in per-
formance were more pronounced in CD patients than in UC pa-
tients. EHS-based valuations were also closer to actual ratings for
clinically relevant subgroups such as the severity stages of CD and
UC patients. Not all variation actually found in the patients with a
high degree of disease severity, however,was reflected by the EHS-
VAS value set, especially for CD patients. A reason for this might
be that the adaptation processes taking place in individuals with
severe restrictions in the general population differ from those of
severely ill patients with inflammatory bowel disease who face a
relatively volatile disease course. From an evaluation perspective,
results of the differences between measurement points seem es-
pecially important as they refer to incremental health effects. For
all patients, the EHS-based value set performed significantly better
than GHS-based value sets in terms of correlation and the
GHS-TTO UK value set in terms of mean absolute error. Compared
with the GHS-TTO Germany value set, the EHS-based value set did
not achieve significantly smaller mean absolute errors for the dif-
ference betweenmeasurement points, although it did so at each of
the two measurement points. In addition to predictive accuracy,
performancewith regard to psychometric characteristics has been
investigated. The EHS-VAS–based approach performed equally
well in terms of construct validity and somewhat better in terms of
test-retest reliability.
The EHS-VAS Germany was developed in a general population
sample that had only covered 49 health states [5]. The study patients
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156 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 5 1 – 1 5 7reported an even lower number of health states. The distribution of
the overall problem score in the clinical populationwas quite similar
to that in the general population sample. The GHS-TTO based ap-
proaches are strong in covering very severehealth states, but this did
not play a role in this sample of patients. Limitations of the EHS-VAS
value set in covering very severe health states did not become rele-
vant; this may have contributed to its relatively good performance.
Other clinical populations, particularly those with more severe con-
ditions, will require respective testing.
On an experience basis, the state of being dead cannot be val-
ued, and the EHS-VAS value set cannot be anchored accordingly.
Quality-adjusted survival can be calculated for the state of being
dead as 0 as survival time is 0. Quality-adjusted survival is also 0
for a health state valued asworst imaginable. This differs from the
quality-adjusted life-year model based on decision utilities in
which GHS are included: GHS-based approaches allow the state of
being dead to be valued and set at 0 for anchoring, thus attributing
negative values to health states worse than death. In empirical
studies, a significant proportion of GHSs described by the EQ-5D
has been valued worse than death, whereas issues in measure-
ment are being debated [18]. If patients experience such a very bad
ealth state, it can be valued in the EHS approach by the VAS, but
his valuation remains on the nonanchored scale. A recent com-
arison of anchored and nonanchored valuations of EQ-5D health
tates has indicated that the impact of anchoring on mean valua-
ions in general population samples (with a distribution of health
tates comparable to that of the current study) may only be minor
19]. The differences in scale should be considered in the use of
HS-based results.
Conclusion
Although traditional approaches to derive value sets are based on
decision utilities and on GHSs, the new value set is based on EHSs.
Fig. 3 – Coverage of EQ-5D health states by problem score: p
TTO UK. Note: Total number of health states occurring show
5, 10, 11. EHS-VAS, experienced health states–visual analogThis study is the first to compare the performance of the EHS-VASbased approach to traditional GHS-TTO–based approaches in a
clinical population. The health states to be predicted by the value
sets were also valued by VAS. Testing for predictive accuracy with
respect to EQ-5D VAS valuations by patients and for test-retest
reliability showed that the EHS-VAS approach performed equally
well or better than the two GHS-based value sets and equally well
when testing for construct validity. The EHS-based value set also
performed somewhat better in patient subgroups, although some-
what better in CD patients than in UC patients.
When it comes to using value sets in patients with inflamma-
tory bowel disease and valuations of own health states are to be
reflected, this study showed that the experience-based approach
works well in terms of predictive performance. Decision makers
who prefer health outcomesmeasured based on actual experience
rather than on decision utilities may choose the EHS-VAS–based
value set as an effective alternative.
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